Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD

Published 07/04/2022, 12:30
Updated 07/04/2022, 13:10
© REUTERS Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
AMD
-
ADVM
-

Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).

  • Adverum requested the FDA's feedback to align with the regulatory agency before filing the Investigational New Drug (IND) amendment for the Phase 2 trial.
  • The trial is designed to evaluate the 2 X 10^11 vg/eye dose, a new, lower 6 X 10^10 vg/eye dose of ADVM-022, and new enhanced prophylactic steroid regimens, including new enhanced prophylactic steroid regimens, local steroids, and a combination of local and systemic steroids.
  • Related: Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD.
  • The company expects to complete the IND amendment process to enable the initiation of the Phase 2 trial of ADVM-022 in wet AMD in mid-2022.
  • Patient dosing in the trial to start in Q3 of 2022.
  • Price Action: ADVM shares closed 3.13% higher at $1.32 during after-hours trading on Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.